Viatris Inc
VTRS · Pharmaceutical Preparations · 1.16B shares · +24%/yr ↑ shares · EDGAR filings ↗
Net buyback after stock comp: $69M (gross $250M, SBC $181M)
Reference price $13.28 · est. market cap ~$15.5B — last insider sale, 2026-03-23 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
C66Large, cash-generative but declining generics/established-brands pharma with strong FCF offset by negative GAAP margins and no growth.
Strengths
- Top-decile cash generation: FCF $1.94B (97th pct), FCF margin 13.6% (80th), OCF margin 16.3% (82nd)
- Diversified global scale (165 countries, 1,400+ molecules) plus five positive Phase 3 readouts (meloxicam, presbyopia, contraceptive patch) seeding an innovative pipeline
Risks
- Revenue declining ~3%, negative GAAP operating margin (-18.7%) and negative interest coverage; weak gross margin (16th pct)
- Base-business erosion (Indore Impact ~$370M), LOE/divestiture drag and high leverage in a no-moat generics model
Notable findings
- No interest coverageInterest coverage -5.65 (cannot cover interest)
- Net lossNet loss (net margin -24.6%)
- Chronic dilutionShare count +24%/yr over 4y (dilution)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- FDA recallFDA recall (Class II) — Xanax XR, alprazolam, extended-release tablets, 3 mg, 60 Tablets bottles, Rx onl (2026-03-17)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Strong balance sheetStrong balance sheet — $1.4B cash & investments
- Insider sellingInsider selling — 1 open-market sale(s) by 1 insider(s) (~$283,539, last 6mo) Form 4 ↗
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, FMR LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-10-31 — PHASE3 · Lupus Erythematosus, Systemic
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
35.1%
Operating margin
-18.6%
Net margin
-24.6%
Return on assets
-9.5%
Revenue growth (QoQ)
-5.0%
Net debt / EBITDA
96.5×
Interest coverage
-5.7×
Current ratio
1.4×
Free cash flow
$1.9B
EBITDA
$135M
Cash & investments
$1.4B
Stock comp / revenue
1.2%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-15 | Le Goff Corinne | Tax withheld | 17K | $13.86 |
| 2026-04-15 | Le Goff Corinne | Option exercise | 39K | — |
| 2026-04-15 | Le Goff Corinne | Option exercise | 3.6K | — |
| 2026-04-15 | Le Goff Corinne | Tax withheld | 1.6K | $13.86 |
| 2026-03-23 | Campbell Paul | Sell | 21K | $13.28 |
| 2026-03-06 | Mistras Theodora | Option exercise | 42K | — |
| 2026-03-06 | Mistras Theodora | Tax withheld | 23K | $14.16 |
| 2026-03-06 | Mistras Theodora | Option exercise | 2.1K | — |
| 2026-03-06 | Mistras Theodora | Tax withheld | 1.1K | $14.16 |
| 2026-03-06 | Enrietti Andrew | Option exercise | 19K | — |
| 2026-03-06 | Enrietti Andrew | Tax withheld | 8.3K | $14.16 |
| 2026-03-06 | Enrietti Andrew | Option exercise | 952 | — |
| 2026-03-06 | Enrietti Andrew | Tax withheld | 415 | $14.16 |
| 2026-03-06 | Campbell Paul | Option exercise | 28K | — |
| 2026-03-06 | Campbell Paul | Tax withheld | 12K | $14.16 |
| 2026-03-06 | Campbell Paul | Option exercise | 1.4K | — |
| 2026-03-06 | Campbell Paul | Tax withheld | 601 | $14.16 |
| 2026-03-06 | Smith Scott Andrew | Option exercise | 125K | — |
| 2026-03-06 | Smith Scott Andrew | Option exercise | 6.2K | — |
| 2026-03-06 | Smith Scott Andrew | Tax withheld | 2.4K | $14.16 |
| 2026-03-06 | Smith Scott Andrew | Tax withheld | 49K | $14.16 |
| 2026-03-06 | Le Goff Corinne | Option exercise | 44K | — |
| 2026-03-06 | Le Goff Corinne | Tax withheld | 20K | $14.16 |
| 2026-03-06 | Le Goff Corinne | Option exercise | 2.2K | — |
| 2026-03-06 | Le Goff Corinne | Tax withheld | 973 | $14.16 |
| 2026-03-06 | SIMMONS DAVID S | Option exercise | 23K | — |
| 2026-03-06 | SIMMONS DAVID S | Option exercise | 524 | — |
| 2026-03-06 | KILTS JAMES M | Option exercise | 24K | — |
| 2026-03-06 | KILTS JAMES M | Option exercise | 1.2K | — |
| 2026-03-06 | Vivaldi Coelho Rogerio | Option exercise | 24K | — |
| 2026-03-06 | Vivaldi Coelho Rogerio | Option exercise | 1.2K | — |
| 2026-03-06 | SEVERINO MICHAEL | Option exercise | 25K | — |
| 2026-03-06 | SEVERINO MICHAEL | Option exercise | 919 | — |
| 2026-03-06 | PARRISH MARK W | Option exercise | 24K | — |
| 2026-03-06 | PARRISH MARK W | Option exercise | 1.2K | — |
| 2026-03-06 | MARK RICHARD A | Option exercise | 24K | — |
| 2026-03-06 | MARK RICHARD A | Option exercise | 1.2K | — |
| 2026-03-06 | HIGGINS MELINA E | Option exercise | 24K | — |
| 2026-03-06 | HIGGINS MELINA E | Option exercise | 1.2K | — |
| 2026-03-06 | Groothuis Leo Frans | Option exercise | 24K | — |
| 2026-03-06 | Groothuis Leo Frans | Tax withheld | 1.2K | $14.16 |
| 2026-03-06 | Groothuis Leo Frans | Option exercise | 1.2K | — |
| 2026-03-06 | Groothuis Leo Frans | Tax withheld | 62 | $14.16 |
| 2026-03-06 | Lyons Dillon JoEllen | Option exercise | 24K | — |
| 2026-03-06 | Lyons Dillon JoEllen | Option exercise | 1.2K | — |
| 2026-03-06 | DAMELIO FRANK A | Option exercise | 25K | — |
| 2026-03-06 | DAMELIO FRANK A | Option exercise | 919 | — |
| 2026-03-06 | CORNWELL W DON | Option exercise | 24K | — |
| 2026-03-06 | CORNWELL W DON | Option exercise | 1.2K | — |
| 2026-03-06 | FINNEY ELISHA W | Option exercise | 24K | — |
| 2026-03-06 | FINNEY ELISHA W | Option exercise | 1.2K | — |
| 2026-03-04 | Smith Scott Andrew | Option exercise | 93K | — |
| 2026-03-04 | Smith Scott Andrew | Tax withheld | 36K | $14.71 |
| 2026-03-04 | Mistras Theodora | Option exercise | 31K | — |
| 2026-03-04 | Mistras Theodora | Tax withheld | 17K | $14.71 |
| 2026-03-04 | Mistras Theodora | Option exercise | 2.9K | — |
| 2026-03-04 | Mistras Theodora | Tax withheld | 1.6K | $14.71 |
| 2026-03-04 | Le Goff Corinne | Option exercise | 37K | — |
| 2026-03-04 | Le Goff Corinne | Tax withheld | 16K | $14.71 |
| 2026-03-04 | Le Goff Corinne | Option exercise | 3.1K | — |
| 2026-03-04 | Le Goff Corinne | Tax withheld | 1.4K | $14.71 |
| 2026-03-04 | Smith Scott Andrew | Option exercise | 8.7K | — |
| 2026-03-04 | Smith Scott Andrew | Tax withheld | 3.4K | $14.71 |
| 2026-03-04 | Enrietti Andrew | Option exercise | 14K | — |
| 2026-03-04 | Enrietti Andrew | Tax withheld | 5.9K | $14.71 |
| 2026-03-04 | Enrietti Andrew | Option exercise | 1.3K | — |
| 2026-03-04 | Enrietti Andrew | Tax withheld | 557 | $14.71 |
| 2026-03-04 | Campbell Paul | Option exercise | 17K | — |
| 2026-03-04 | Campbell Paul | Tax withheld | 7.5K | $14.71 |
| 2026-03-04 | Campbell Paul | Option exercise | 1.6K | — |
| 2026-03-04 | Campbell Paul | Tax withheld | 706 | $14.71 |
| 2026-03-03 | Smith Scott Andrew | Option exercise | 136K | — |
| 2026-03-03 | Smith Scott Andrew | Tax withheld | 53K | $14.89 |
| 2026-03-03 | Campbell Paul | Option exercise | 18K | — |
| 2026-03-03 | Campbell Paul | Tax withheld | 7.9K | $14.89 |
| 2026-03-03 | Campbell Paul | Option exercise | 2.6K | — |
| 2026-03-03 | Campbell Paul | Tax withheld | 1.1K | $14.89 |
| 2026-03-03 | Campbell Paul | Option exercise | 170K | — |
| 2026-03-03 | Campbell Paul | Tax withheld | 74K | $14.89 |
| 2026-03-03 | Enrietti Andrew | Option exercise | 12K | — |
| 2026-03-03 | Enrietti Andrew | Tax withheld | 5.1K | $14.89 |
| 2026-03-03 | Smith Scott Andrew | Option exercise | 18K | — |
| 2026-03-03 | Smith Scott Andrew | Tax withheld | 7.1K | $14.89 |
| 2026-03-03 | Enrietti Andrew | Option exercise | 1.7K | — |
| 2026-03-03 | Enrietti Andrew | Tax withheld | 744 | $14.89 |
| 2026-03-03 | Enrietti Andrew | Option exercise | 111K | — |
| 2026-03-03 | Enrietti Andrew | Tax withheld | 48K | $14.89 |
| 2026-03-03 | Smith Scott Andrew | Option exercise | 1.3M | — |
| 2026-03-03 | Smith Scott Andrew | Tax withheld | 506K | $14.89 |
| 2026-01-01 | Mistras Theodora | Tax withheld | 13K | $12.45 |
| 2026-01-01 | Mistras Theodora | Option exercise | 23K | — |
| 2026-01-01 | Mistras Theodora | Option exercise | 2.2K | — |
| 2026-01-01 | Mistras Theodora | Tax withheld | 1.2K | $12.45 |
| 2025-11-03 | SIMMONS DAVID S | Buy | 213 | $10.43 |
| 2025-09-11 | Le Goff Corinne | Sell | 7.0K | $10.25 |
| 2025-08-27 | SIMMONS DAVID S | Buy | 286 | $10.42 |
| 2025-08-12 | Smith Scott Andrew | Buy | 22K | $9.99 |
| 2025-05-12 | Smith Scott Andrew | Buy | 60K | $8.94 |
| 2025-04-15 | Le Goff Corinne | Tax withheld | 855 | $7.48 |
| 2025-04-15 | Le Goff Corinne | Option exercise | 39K | — |
| 2025-04-15 | Le Goff Corinne | Option exercise | 1.8K | — |
| 2025-04-15 | Le Goff Corinne | Tax withheld | 19K | $7.48 |
| 2025-03-04 | FINNEY ELISHA W | Option exercise | 18K | — |
| 2025-03-04 | FINNEY ELISHA W | Option exercise | 773 | — |
| 2025-03-04 | Le Goff Corinne | Option exercise | 37K | — |
| 2025-03-04 | Le Goff Corinne | Tax withheld | 16K | $9.37 |
| 2025-03-04 | Le Goff Corinne | Option exercise | 1.2K | — |
| 2025-03-04 | Le Goff Corinne | Tax withheld | 521 | $9.37 |
| 2025-03-04 | Roman Brian | Option exercise | 992 | — |
| 2025-03-04 | KORMAN HARRY | Option exercise | 18K | — |
| 2025-03-04 | KORMAN HARRY | Option exercise | 773 | — |
| 2025-03-04 | Groothuis Leo Frans | Option exercise | 18K | — |
| 2025-03-04 | Groothuis Leo Frans | Tax withheld | 1.2K | $9.37 |
| 2025-03-04 | Groothuis Leo Frans | Option exercise | 773 | — |
| 2025-03-04 | Groothuis Leo Frans | Tax withheld | 50 | $9.37 |
| 2025-03-04 | CORNWELL W DON | Option exercise | 18K | — |
| 2025-03-04 | CORNWELL W DON | Option exercise | 773 | — |
| 2025-03-04 | Malik Rajiv | Option exercise | 602 | — |
| 2025-03-04 | Malik Rajiv | Option exercise | 780K | — |
| 2025-03-04 | Malik Rajiv | Tax withheld | 339K | $9.37 |
| 2025-03-04 | KILTS JAMES M | Option exercise | 18K | — |
| 2025-03-04 | KILTS JAMES M | Option exercise | 773 | — |
| 2025-03-04 | MARK RICHARD A | Option exercise | 18K | — |
| 2025-03-04 | MARK RICHARD A | Option exercise | 773 | — |
| 2025-03-04 | Roman Brian | Option exercise | 17K | — |
| 2025-03-04 | Roman Brian | Tax withheld | 7.5K | $9.37 |
| 2025-03-04 | Roman Brian | Option exercise | 2.3K | — |
| 2025-03-04 | Roman Brian | Tax withheld | 1.0K | $9.37 |
| 2025-03-04 | Roman Brian | Option exercise | 23K | — |
| 2025-03-04 | Roman Brian | Tax withheld | 10K | $9.37 |
| 2025-03-04 | Roman Brian | Tax withheld | 435 | $9.37 |
| 2025-03-04 | Roman Brian | Option exercise | 162K | — |
| 2025-03-04 | Roman Brian | Tax withheld | 71K | $9.37 |
| 2025-03-04 | Mistras Theodora | Option exercise | 31K | — |
| 2025-03-04 | Mistras Theodora | Tax withheld | 17K | $9.37 |
| 2025-03-04 | Mistras Theodora | Option exercise | 1.3K | — |
| 2025-03-04 | Mistras Theodora | Tax withheld | 732 | $9.37 |
| 2025-03-04 | Campbell Paul | Option exercise | 18K | — |
| 2025-03-04 | Campbell Paul | Tax withheld | 7.8K | $9.37 |
| 2025-03-04 | Campbell Paul | Option exercise | 2.4K | — |
| 2025-03-04 | Campbell Paul | Tax withheld | 1.0K | $9.37 |
| 2025-03-04 | Campbell Paul | Option exercise | 17K | — |
| 2025-03-04 | Campbell Paul | Tax withheld | 7.5K | $9.37 |
| 2025-03-04 | Campbell Paul | Option exercise | 727 | — |
| 2025-03-04 | Campbell Paul | Tax withheld | 319 | $9.37 |
| 2025-03-04 | Campbell Paul | Option exercise | 169K | — |
| 2025-03-04 | Campbell Paul | Tax withheld | 74K | $9.37 |
| 2025-03-04 | Vivaldi Coelho Rogerio | Option exercise | 21K | — |
| 2025-03-04 | Vivaldi Coelho Rogerio | Option exercise | 424 | — |
| 2025-03-04 | Smith Scott Andrew | Option exercise | 93K | — |
| 2025-03-04 | Smith Scott Andrew | Tax withheld | 36K | $9.37 |
| 2025-03-04 | Smith Scott Andrew | Option exercise | 3.9K | — |
| 2025-03-04 | Smith Scott Andrew | Tax withheld | 1.5K | $9.37 |
| 2025-03-04 | PARRISH MARK W | Option exercise | 18K | — |
| 2025-03-04 | PARRISH MARK W | Option exercise | 773 | — |
| 2025-03-04 | Lyons Dillon JoEllen | Option exercise | 18K | — |
| 2025-03-04 | Lyons Dillon JoEllen | Option exercise | 773 | — |
| 2025-03-04 | HIGGINS MELINA E | Option exercise | 18K | — |
| 2025-03-04 | HIGGINS MELINA E | Option exercise | 773 | — |
| 2025-03-04 | Malik Rajiv | Option exercise | 82K | — |
| 2025-03-04 | Malik Rajiv | Tax withheld | 36K | $9.37 |
| 2025-03-04 | Malik Rajiv | Option exercise | 11K | — |
| 2025-03-04 | Malik Rajiv | Tax withheld | 4.8K | $9.37 |
| 2025-03-04 | Malik Rajiv | Option exercise | 19K | — |
| 2025-03-03 | Campbell Paul | Option exercise | 18K | — |
| 2025-03-03 | Campbell Paul | Option exercise | 1.7K | — |
| 2025-03-03 | Campbell Paul | Tax withheld | 727 | $9.33 |
| 2025-03-03 | Campbell Paul | Tax withheld | 7.9K | $9.33 |
| 2025-03-03 | Smith Scott Andrew | Tax withheld | 53K | $9.33 |
| 2025-03-03 | Smith Scott Andrew | Option exercise | 11K | — |
| 2025-03-03 | Smith Scott Andrew | Tax withheld | 4.3K | $9.33 |
| 2025-03-03 | Malik Rajiv | Tax withheld | 3.3K | $9.33 |
| 2025-03-03 | Roman Brian | Option exercise | 17K | — |
| 2025-03-03 | Roman Brian | Tax withheld | 7.4K | $9.33 |
| 2025-03-03 | Roman Brian | Option exercise | 1.6K | — |
| 2025-03-03 | Roman Brian | Tax withheld | 690 | $9.33 |
| 2025-03-03 | Malik Rajiv | Option exercise | 82K | — |
| 2025-03-03 | Malik Rajiv | Tax withheld | 37K | $9.33 |
| 2025-03-03 | Malik Rajiv | Option exercise | 7.7K | — |
| 2025-03-03 | Smith Scott Andrew | Option exercise | 136K | — |
| 2025-01-01 | Mistras Theodora | Tax withheld | 13K | $12.45 |
| 2025-01-01 | Mistras Theodora | Tax withheld | 523 | $12.45 |
| 2025-01-01 | Mistras Theodora | Option exercise | 23K | — |
| 2025-01-01 | Mistras Theodora | Option exercise | 981 | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07201129 ↗ | A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment Nephritis, Lupus, Lupus Erythematosus, Systemic | PHASE3 | Recruiting | 2029-08-01 |
| NCT06475742 ↗ | Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus Lupus Erythematosus, Systemic | PHASE3 | Enrolling By Invitation | 2028-05-01 |
| NCT07266090 ↗ | A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE) SLE - Systemic Lupus Erythematosus | PHASE2 | Active Not Recruiting | 2027-10-08 |
| NCT04957719 ↗ | Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Acute Myocardial Infarction | PHASE3 | Enrolling By Invitation | 2026-12-01 |
| NCT05648500 ↗ | A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus Lupus Erythematosus, Systemic | PHASE3 | Active Not Recruiting | 2026-10-31 |
| NCT05672576 ↗ | A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus Lupus Erythematosus, Systemic | PHASE3 | Active Not Recruiting | 2026-10-31 |
| NCT06052995 ↗ | Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis. Mild to Moderate Atopic Dermatitis | — | Active Not Recruiting | 2026-10-01 |
| NCT06471088 ↗ | Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance Dovprela | — | Recruiting | 2026-06-30 |
| NCT07597473 ↗ | Dymista in Chinese Adolescents Allergic Rhinitis Due to Allergens | PHASE4 | Not Yet Recruiting | 2027-03-01 |
| NCT07615868 ↗ | A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Chinese Adults With Chronic Coronary Syndrome Chronic Coronary Syndrome | PHASE1 | Not Yet Recruiting | 2026-10-01 |
| NCT07301723 ↗ | A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants Healthy Subjects | PHASE1 | Completed | 2026-03-18 |
| NCT07133191 ↗ | A Trial to Compare What the Body Does to Selatogrel and the Effect of Selatogrel in Japanese and Caucasian Healthy Participants Healthy Volunteers | PHASE1 | Completed | 2025-11-05 |
| NCT06400511 ↗ | A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment Blepharitis | PHASE3 | Terminated | 2025-09-09 |
| NCT06215859 ↗ | Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Herniorrhaphy Acute Pain, Post Operative Pain | PHASE3 | Completed | 2025-01-31 |
| NCT06215820 ↗ | Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy Acute Pain, Post Operative Pain | PHASE3 | Completed | 2024-08-24 |
| NCT04819464 ↗ | A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod Healthy, Hepatic Impairment | PHASE1 | Completed | 2024-08-18 |
| NCT06273254 ↗ | A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions Bioequivalence Study | PHASE1 | Unknown | 2024-05-01 |
| NCT06266988 ↗ | A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions Chronic Heart Failure | PHASE1 | Unknown | 2024-04-01 |
| NCT05004311 ↗ | The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics Healthy, Renal Impairment | PHASE1 | Completed | 2023-07-27 |
| NCT04570436 ↗ | Evaluating the Abuse Potential of NEURONTIN® When Taken Orally in Healthy Non-drug Dependent Participants With Sedative Drug Abuse Experience Abuse Potential | PHASE4 | Completed | 2022-11-10 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Supply chain
Customers (0)
Suppliers (1)
Named in the 10-K; linked when we track them.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-18 | Material agreementDebt obligationExhibits | filing ↗ |
| 2026-06-15 | OtherExhibits | filing ↗ |
| 2026-05-15 | Shareholder vote | filing ↗ |
| 2026-05-07 | ResultsOtherExhibits | filing ↗ |
| 2026-05-04 | Exec/director changeReg FDExhibits | filing ↗ |
| 2026-02-26 | Results2.05OtherExhibits | filing ↗ |
| 2026-02-03 | Exec/director change | filing ↗ |
| 2025-12-08 | Reg FDExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-18 | 2026-06-17 | 0001140361-26-025744 ↗ |
| 8-K | 2026-06-15 | 2026-06-12 | 0001140361-26-025228 ↗ |
| 8-K | 2026-05-15 | 2026-05-15 | 0001140361-26-021672 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001792044-26-000025 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001792044-26-000029 ↗ |
| 8-K | 2026-05-04 | 2026-05-01 | 0001140361-26-018887 ↗ |
| 8-K | 2026-02-26 | 2026-02-23 | 0001792044-26-000010 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0001792044-26-000013 ↗ |
| 8-K | 2026-02-03 | 2026-01-29 | 0001140361-26-003477 ↗ |
| 8-K | 2025-12-08 | 2025-12-08 | 0001140361-25-044706 ↗ |
| 8-K | 2025-12-05 | 2025-12-05 | 0001140361-25-044544 ↗ |
| 8-K/A | 2025-12-05 | 2025-08-04 | 0001140361-25-044541 ↗ |